Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.48 |
| ▸ | IGF2R | P11717 | 4/20 | 0.40 |
| ▸ | UMPS | P11172 | 3/20 | 0.40 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.39 |
| ▸ | ATIC | P31939 | 1/20 | 0.38 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722795 | 0.82 | PGD (0.37) | FBP1ADSS2P2RY2 | |
| SCHEMBL14928456 | 0.80 | FBP1 (0.46) | FBP1IGF2RUMPSDNPH1ADSS2 | |
| SCHEMBL18561552 | 0.78 | P2RY2 (0.46) | P2RY2P2RY6 | |
| SCHEMBL4635574 | 0.74 | FBP1 (0.57) | FBP1IGF2RUMPSDNPH1ADSS2 | |
| SCHEMBL25843145 | 0.73 | FBP1 (0.46) | FBP1UMPSDNPH1ATICP2RY2 | |
| SCHEMBL19679997 | 0.72 | FBP1 (0.48) | FBP1UMPSDNPH1ADSS2ATIC | |
| SCHEMBL14928570 | 0.72 | FBP1 (0.48) | FBP1IGF2RUMPSDNPH1ADSS2 | |
| SCHEMBL25624133 | 0.72 | FBP1 (0.48) | FBP1IGF2RUMPSDNPH1ADSS2 | |
| SCHEMBL16450259 | 0.71 | UMPS (0.48) | FBP1UMPSDNPH1ATICHPRT1 | |
| SCHEMBL15277191 | 0.71 | UMPS (0.48) | FBP1UMPSDNPH1ATICHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | FBP1 4249/4885IGF2R 3029/4885UMPS 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.